These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 2730278)
1. Hyperresponsivity to the serotonin agonist m-chlorophenylpiperazine in Alzheimer's disease. A controlled study. Lawlor BA; Sunderland T; Mellow AM; Hill JL; Molchan SE; Murphy DL Arch Gen Psychiatry; 1989 Jun; 46(6):542-9. PubMed ID: 2730278 [TBL] [Abstract][Full Text] [Related]
2. m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Evidence implicating serotonergic systems in the positive symptoms of schizophrenia. Krystal JH; Seibyl JP; Price LH; Woods SW; Heninger GR; Aghajanian GK; Charney DS Arch Gen Psychiatry; 1993 Aug; 50(8):624-35. PubMed ID: 8102048 [TBL] [Abstract][Full Text] [Related]
3. Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. Charney DS; Goodman WK; Price LH; Woods SW; Rasmussen SA; Heninger GR Arch Gen Psychiatry; 1988 Feb; 45(2):177-85. PubMed ID: 3337615 [TBL] [Abstract][Full Text] [Related]
4. Serotonin function in schizophrenia: effects of meta-chlorophenylpiperazine in schizophrenic patients and healthy subjects. Kahn RS; Siever LJ; Gabriel S; Amin F; Stern RG; DuMont K; Apter S; Davidson M Psychiatry Res; 1992 Jul; 43(1):1-12. PubMed ID: 1332094 [TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine and behavioral effects of m-chlorophenylpiperazine administration in rhesus monkeys. Aloi JA; Insel TR; Mueller EA; Murphy DL Life Sci; 1984 Apr; 34(14):1325-31. PubMed ID: 6708733 [TBL] [Abstract][Full Text] [Related]
6. Serotonin dysregulation in adolescents with major depression: hormone response to meta-chlorophenylpiperazine (mCPP) infusion. Ghaziuddin N; King CA; Welch KB; Zaccagnini J; Weidmer-Mikhail E; Mellow AM; Ghaziuddin M; Greden JF Psychiatry Res; 2000 Sep; 95(3):183-94. PubMed ID: 10974357 [TBL] [Abstract][Full Text] [Related]
7. The effects of administration of mCPP on psychological, cognitive, cardiovascular, hormonal and MHPG measurements in human volunteers. Silverstone PH; Rue JE; Franklin M; Hallis K; Camplin G; Laver D; Cowen PJ Int Clin Psychopharmacol; 1994 Sep; 9(3):173-8. PubMed ID: 7814826 [TBL] [Abstract][Full Text] [Related]
8. The MCPP challenge test in schizophrenia: hormonal and behavioral responses. Iqbal N; Asnis GM; Wetzler S; Kahn RS; Kay SR; van Praag HM Biol Psychiatry; 1991 Oct; 30(8):770-8. PubMed ID: 1751620 [TBL] [Abstract][Full Text] [Related]
9. Central serotonergic effects of m-chlorophenylpiperazine (mCPP) among normal control adolescents. Ghaziuddin N; Welch K; Greden J Neuropsychopharmacology; 2003 Jan; 28(1):133-9. PubMed ID: 12496949 [TBL] [Abstract][Full Text] [Related]
10. Serotonergic and noradrenergic dysregulation in alcoholism: m-chlorophenylpiperazine and yohimbine effects in recently detoxified alcoholics and healthy comparison subjects. Krystal JH; Webb E; Cooney NL; Kranzler HR; Southwick SW; Heninger GR; Charney DS Am J Psychiatry; 1996 Jan; 153(1):83-92. PubMed ID: 8540598 [TBL] [Abstract][Full Text] [Related]
11. Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Charney DS; Woods SW; Goodman WK; Heninger GR Psychopharmacology (Berl); 1987; 92(1):14-24. PubMed ID: 3110824 [TBL] [Abstract][Full Text] [Related]
12. Effects of meta-chlorophenylpiperazine on neuroendocrine and behavioral responses in male schizophrenic patients and normal volunteers. Maes M; Meltzer HY Psychiatry Res; 1996 Oct; 64(3):147-59. PubMed ID: 8944393 [TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine and behavioral responses to intravenous m-chlorophenylpiperazine (mCPP) in depressed patients and healthy comparison subjects. Anand A; Charney DS; Delgado PL; McDougle CJ; Heninger GR; Price LH Am J Psychiatry; 1994 Nov; 151(11):1626-30. PubMed ID: 7943451 [TBL] [Abstract][Full Text] [Related]
14. Effect of m-chlorophenylpiperazine on plasma homovanillic acid concentrations in healthy subjects. Kahn RS; Knott P; Gabriel S; DuMont K; Mastroianni L; Davidson M Biol Psychiatry; 1992 Dec; 32(11):1055-61. PubMed ID: 1467386 [TBL] [Abstract][Full Text] [Related]
15. Effects of alprazolam on increases in hormonal and anxiety levels induced by meta-chlorophenylpiperazine. Sevy S; Brown SL; Wetzler S; Kotler M; Molcho A; Plutchik R; van Praag HM Psychiatry Res; 1994 Sep; 53(3):219-29. PubMed ID: 7870844 [TBL] [Abstract][Full Text] [Related]
16. Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder. Hollander E; DeCaria C; Gully R; Nitescu A; Suckow RF; Gorman JM; Klein DF; Liebowitz MR Psychiatry Res; 1991 Jan; 36(1):1-17. PubMed ID: 2017519 [TBL] [Abstract][Full Text] [Related]
17. Specificity of ethanollike effects elicited by serotonergic and noradrenergic mechanisms. Krystal JH; Webb E; Cooney N; Kranzler HR; Charney DS Arch Gen Psychiatry; 1994 Nov; 51(11):898-911. PubMed ID: 7944878 [TBL] [Abstract][Full Text] [Related]
18. m-Chlorophenylpiperazine as a probe of serotonin function. Kahn RS; Wetzler S Biol Psychiatry; 1991 Dec; 30(11):1139-66. PubMed ID: 1663792 [TBL] [Abstract][Full Text] [Related]
19. Effect of meta-chlorophenylpiperazine (mCPP), a central serotonin agonist and vascular serotonin receptor antagonist, on blood pressure in SHR. Cohen ML; Kurz KD; Fuller RW Clin Exp Hypertens A; 1987; 9(10):1549-65. PubMed ID: 3677442 [TBL] [Abstract][Full Text] [Related]